Lana Gettman
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Role not yet determined Is this you? Add your title
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Lana Gettman's research and publications focus on advancements in pharmaceutical treatments, particularly for chronic and infectious diseases. Her recent work includes reviews of novel drugs such as Lecanemab-irmb for Alzheimer's disease and Tirzepatide for type 2 diabetes. She has also published on Finerenone, Difelikefalin, and Avacopan, as well as Faricimab-svoa for macular degeneration and Omidenepag Isopropyl for glaucoma. Gettman has also contributed to the understanding of treatments for SARS-CoV-2, with publications detailing three novel therapies. Beyond drug development, her scholarly interests extend to pharmacy education, including a focus on implementing proactive support models to enhance student success and assessing skills in interpreting culture and sensitivity reports. Gettman's scholarship metrics include an h-index of 5 and 14 total publications.
Metrics
- h-index: 5
- Publications: 14
- Citations: 66
Selected Publications
-
Developing professional etiquette and networking skills in pharmacy students: Evaluation of an etiquette dinner program (2026)
-
Practicing and Assessing Skills of Interpreting Culture and Sensitivity Reports (2025)Scholar Works at Harding (Harding University Main Campus) OpenAlex
-
Advancing Student Success: Implementation of a Proactive Support Model at a College of Pharmacy (2025)
-
Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer’s Disease (2024)
-
New Drugs: Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension (2023)
-
New Drug: Tirzepatide (Mounjaro™) (2023)
-
New Drugs Update: Three Novel Treatments for SARS-CoV-2 (2022)
-
New Drugs Update: Finerenone, Difelikefalin, and Avacopan (2022)
-
New Drugs (2021)
-
Aspire to be smoke-free pilot study: A prevention educational outreach serving preschool children in rural Arkansas (2020)
-
Descriptive Analysis of Acceptance by Prescribers and Economic Benefit of Pharmacist Recommended Interventions in a Critical Care Unit (2018)
Collaboration Network
Top Collaborators
- Descriptive Analysis of Acceptance by Prescribers and Economic Benefit of Pharmacist Recommended Interventions in a Critical Care Unit
- Aspire to be smoke-free pilot study: A prevention educational outreach serving preschool children in rural Arkansas
- Aspire to be smoke-free pilot study: A prevention educational outreach serving preschool children in rural Arkansas
- Aspire to be smoke-free pilot study: A prevention educational outreach serving preschool children in rural Arkansas
- Advancing Student Success: Implementation of a Proactive Support Model at a College of Pharmacy
- Advancing Student Success: Implementation of a Proactive Support Model at a College of Pharmacy
Similar Researchers
Based on overlapping research topics